Drugs / omefas
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01486433 | Nov 2011 → Mar 2012 | hypertriglyceridemia | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01431690 | Aug → Oct 2011 | hypertriglyceridemia | AstraZeneca | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01242527 | Jan 2011 → Mar 2012 | — | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | omefas | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01486433 ↗ |
| Known as | Epanova | “Efficacy and Safety of Epanova® (Omefas) in Severe Hypertriglyceridemia” NCT01242527 ↗ |